Goserelin

Goserelin (Zoladex) is a real, FDA-approved GnRH agonist delivered as a small implant rather than an injection — notable for having one of the widest indication ranges in this drug class, covering prostate cancer, breast cancer, and endometriosis.

A different delivery format, same mechanism

Goserelin is a decapeptide GnRH agonist, mechanistically identical to leuprolide and triptorelin — continuous agonist stimulation eventually downregulates the pituitary GnRH receptor and suppresses testosterone or estrogen. Its structural modifications are its own combination: a D-Ser(tBu) substitution at position 6 plus an aza-glycine C-terminal amide, both intended to resist enzymatic degradation. The more practically notable difference is delivery: goserelin is implanted as a small biodegradable rod under the skin rather than injected as a suspension, a genuinely different manufacturing and administration format from the other two.

Three separate approved indications

The FDA first approved goserelin (as Zoladex, 3.6mg implant) on 29 December 1989 for advanced prostate cancer. It has since been approved for early breast cancer in premenopausal women (as an alternative to surgical oophorectomy) and for endometriosis-related pelvic pain (up to 6 months of continuous use) — we could not confirm the exact approval dates for those two supplemental indications and would treat "early-to-mid 1990s" as an approximate rather than confirmed date for the breast cancer indication specifically. The strongest citable trial for the breast cancer indication is the ZEBRA trial (Zoladex Early Breast Cancer Research Association, Eur J Cancer 2003, PMID 12888366): 1,640 premenopausal, node-positive patients across 102 centers, comparing goserelin to CMF chemotherapy, which found non-inferiority for overall and disease-free survival in estrogen-receptor-positive disease specifically (goserelin performed worse than CMF in ER-negative disease). For prostate cancer, an earlier randomized trial against surgical orchiectomy (PMID 7624991, Urology 1995, n=283) found similar objective response (82% vs. 77%), time to treatment failure, and survival between the two approaches.

The flare, and the same 2010 class warning

Same flare mechanism as other GnRH agonists — transient rise in testosterone/estradiol and possible tumor-symptom flare in the first weeks, managed with anti-androgen co-therapy in prostate cancer patients at risk of complications. Goserelin was one of the drugs named in the FDA's October 2010 class-wide safety label update for GnRH agonists regarding increased risk of diabetes and cardiovascular events.

Current status

Still marketed by AstraZeneca. Patent protection has reportedly lapsed, but we could not confirm an FDA-approved US generic goserelin implant exists as of this review — the implant's manufacturing complexity may be a factor, and this is worth checking directly against the FDA's Orange Book before assuming generic availability. We did not run an exhaustive grey-market vendor search for goserelin specifically (its implant format makes it a poor fit for simple online "research chemical" sale compared to a lyophilized powder), and found no FDA warning letter naming it.